Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

NCT02913261 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

310

Enrollment

INDUSTRY

Sponsor class

Conditions

Corticosteroid Refractory Acute Graft vs Host Disease

Interventions

DRUG: Ruxolitinib (RUX)
DRUG: Best Available Therapy (BAT)

Sponsor

Novartis Pharmaceuticals